Mi­crosoft sinks deep­er in­to drug AI, inks col­lab with di­a­betes gi­ant No­vo Nordisk

It now ap­pears that Mi­crosoft wants to take on di­a­betes.

In its lat­est for­ay in­to the drug­mak­ing world, the tech gi­ant has signed a five-year pact with No­vo Nordisk, one of the three ma­jor in­sulin man­u­fac­tur­ers. The ex­act de­tails of the part­ner­ship are vague (as most AI part­ner­ship an­nounce­ments tend to be), but in short, No­vo Nordisk will be pay­ing Mi­crosoft for its AI to speed drug de­vel­op­ment.

Ac­cord­ing to the press re­lease, the col­lab­o­ra­tion has al­ready made strides on two fronts: (1) sum­ma­riz­ing sci­en­tif­ic re­search, and (2) to study ath­er­o­scle­ro­sis — a ma­jor com­pli­ca­tion of di­a­betes.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER